An interventional study of combined exercise and nutrition intervention in Ovarian Cancer, Malnutrition and Muscle Wasting, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 7 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Ovarian Neoplasms with a site in Germany — 34 open to participants now, 54 under way, 19 of them phase 3. Ovarian Neoplasms · Germany.
Among the 189 studies in Ovarian Neoplasms with a site in Germany, this one is the 98th largest by planned enrollment of the 163 interventional ones that give a count, is one of 10 that started in 2024, is one of 16 with no phase, reaches primary completion later than 9 of the 53 other live ones, and was the 168th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →34 of the 189 studies in Ovarian Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United States, Australia and 10 more countries
Ages 18+ · Women only
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in Germany, United States, Argentina and 19 more countries
Ages 18+ · Women only
Genmab · Sites in Germany, United States, Australia and 13 more countries
Ages 18+ · Women only
Boehringer Ingelheim · Sites in Germany, United States, Belgium and 3 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 27 more countries
Ages 18+ · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 74 · Phase 3 62 · Phase 4 1
First in 1995; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 185 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 250 across the 163 interventional studies, 530 across the 23 observational. Of the 120 that completed or were terminated, 41 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 189 have an industry lead sponsor. The 10 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Universitätsklinikum Hamburg-Eppendorf has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Ovarian Neoplasms with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT07214779Phase 3Incyte CorporationStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | 2027-10-12 |
| NCT01789229Medical University of ViennaEstablishment of a Tumor Bank for Tissue Samples | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 189 studies in Ovarian Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this multicenter randomized controlled trial is to compare a 6-month exercise and nutrition intervention (intervention group, IG) aimed at maintaining or improving physical functioning and quality of life with usual care (control group, CG) in ovarian cancer patients.
The main question it aims to answer is:
Participants of the IG will undergo:
The study design includes 3 survey time points:
The primary outcome is:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
usual care
6 month exercise and nutrition intervention
Behavioral: combined exercise and nutrition intervention
Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
6 Minute Walk Test (distance in metre)
Sub-maximal exercise test used to assess aerobic capacity and endurance
Time frame: Change in the total distance from T2 (6 months after enrollment) to baseline as target
6 Minute Walk Test (distance in metre)
Sub-maximal exercise test used to assess aerobic capacity and endurance
Time frame: Change in the total distance from T1 (end of chemotherapy, approx. week 18-19) to baseline as target
Global physical activity questionnaire (GPAQ)
Physical activity in minutes per day, MET minutes per week
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Assessment of body composition using bioelectrical impedance analysis (BIA)
Bioelectrical impedance analyzers use an alternating electric current to measure the two components of bioelectrical impedance in the human body, resistance r and reactance Xc. In electrophysiological terms, resistance (per unit volume) correlates negatively with the amount of body fluid (body water and fat-free mass (FFM)) through which the current flows, while reactance correlates positively with the mass of body cells. The magnitude of Xc in relation to R is expressed as the phase angle (PA). From the measured R and Xc values and other subject data, additional indicators of body composition (e.g., total body water, fat-free mass, and fat mass) can be estimated using specific prediction equations based on modeling assumptions that are generally population-, age-, sex-, fat-, and disease-specific.
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Grip force dynamometer
Hand gripping force (kg)
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Polyneuropathy; item derived from EORTC CIPN20 (Item 9)
Problems standing or walking, because can't longer feel the ground under feet
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Patient Health Questionnaire-9 (PHQ-9)
Depression screening
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Generalized Anxiety Disorder using GAD-2
Anxiety
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Adherence to a Mediterranean diet (MEDAS)
Adherence to a Mediterranean diet is assessed using the 14-item Mediterranean Diet Adherence Screener (MEDAS).
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
EORTC QLQ-C30
Quality of life (multidimensional) across 10 subscales
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
EORTC OV-28
Quality of life (multidimensional) focusing on ovarian cancer across 7 subscales
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
EORT FA-12
Quality of life (multidimensional) focusing on fatigue
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Nutritional Risk Screening (NRS 2002)
Malnutrition risk
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Brief Social Support Scale (BS6)
Social support (tangible support, emotional-informational support)
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Patient Activation Measure (PAM-13)
Patient Activation Measure
Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))
Plan to share: No — The study protocol will be published in a peer-reviewed journal at the outset. The Statistical Analysis Plan (SAP), Informed Consent Form (ICF), and analysis code will be provided upon request, if available at the time of request.
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jul 2025, 18 months after the start.
Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 18 months is below that.
Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf →